JP2002537816A5 - - Google Patents

Download PDF

Info

Publication number
JP2002537816A5
JP2002537816A5 JP2000602796A JP2000602796A JP2002537816A5 JP 2002537816 A5 JP2002537816 A5 JP 2002537816A5 JP 2000602796 A JP2000602796 A JP 2000602796A JP 2000602796 A JP2000602796 A JP 2000602796A JP 2002537816 A5 JP2002537816 A5 JP 2002537816A5
Authority
JP
Japan
Prior art keywords
adenovirus
subgroup
recombinant
serotype
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000602796A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002537816A (ja
JP4683727B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/NL2000/000133 external-priority patent/WO2000052186A1/en
Publication of JP2002537816A publication Critical patent/JP2002537816A/ja
Publication of JP2002537816A5 publication Critical patent/JP2002537816A5/ja
Application granted granted Critical
Publication of JP4683727B2 publication Critical patent/JP4683727B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2000602796A 1999-03-04 2000-03-03 線維芽細胞様またはマクロファージ様細胞の形質導入のための手段と方法 Expired - Fee Related JP4683727B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99200624 1999-03-04
EP99200624.7 1999-03-04
PCT/NL2000/000133 WO2000052186A1 (en) 1999-03-04 2000-03-03 Means and methods for fibroblast-like or macrophage-like cell transduction

Publications (3)

Publication Number Publication Date
JP2002537816A JP2002537816A (ja) 2002-11-12
JP2002537816A5 true JP2002537816A5 (enExample) 2011-02-24
JP4683727B2 JP4683727B2 (ja) 2011-05-18

Family

ID=8239945

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000602796A Expired - Fee Related JP4683727B2 (ja) 1999-03-04 2000-03-03 線維芽細胞様またはマクロファージ様細胞の形質導入のための手段と方法

Country Status (7)

Country Link
EP (1) EP1159438B1 (enExample)
JP (1) JP4683727B2 (enExample)
AT (1) ATE403006T1 (enExample)
AU (1) AU776067B2 (enExample)
CA (1) CA2364499C (enExample)
DE (1) DE60039683D1 (enExample)
WO (1) WO2000052186A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6783980B2 (en) 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US6929946B1 (en) 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
US6869936B1 (en) 1999-03-04 2005-03-22 Crucell Holland B.V. Means and methods for fibroblast-like or macrophage-like cell transduction
EP1816204B1 (en) * 1999-05-17 2010-10-20 Crucell Holland B.V. Recombinant Adenovirus of the Ad26 serotype
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
EP1067188A1 (en) * 1999-07-08 2001-01-10 Introgene B.V. Infection with chimaeric adenoviruses of cells negative for the adenovirus serotype 5 Coxsacki adenovirus receptor (CAR)
WO2002012523A2 (en) * 2000-08-10 2002-02-14 Crucell Holland B.V. Transduction of chondrocytes using adenoviral vectors
WO2002024730A2 (en) * 2000-09-20 2002-03-28 Crucell Holland B.V. Transduction of dendritic cells using adenoviral vectors
US7235233B2 (en) 2000-09-26 2007-06-26 Crucell Holland B.V. Serotype 5 adenoviral vectors with chimeric fibers for gene delivery in skeletal muscle cells or myoblasts
AU2002211087A1 (en) * 2000-10-06 2002-04-15 Crucell Holland B.V. Gene delivery vectors for stem cells
EP1195440A1 (en) * 2000-10-06 2002-04-10 Introgene B.V. Gene delivery vectors for stem cells
EP1279738A1 (en) * 2001-07-06 2003-01-29 Crucell Holland B.V. Gene delivery vectors with cell type specificity for mesenchymal stem cells
US6905678B2 (en) * 2001-07-07 2005-06-14 Crucell Holland B.V. Gene delivery vectors with cell type specificity for mesenchymal stem cells
ES2335657T3 (es) 2002-04-25 2010-03-31 Crucell Holland B.V. Medios y metodos para la produccion de vectores de adenovirus.
WO2004001032A2 (en) 2002-04-25 2003-12-31 Crucell Holland B.V. Stable adenoviral vectors and methods for propagation thereof
EP1553983A2 (en) 2002-10-23 2005-07-20 Crucell Holland B.V. New settings for recombinant adenoviral-based vaccines
US20080153083A1 (en) 2003-10-23 2008-06-26 Crucell Holland B.V. Settings for recombinant adenoviral-based vaccines
NZ539813A (en) 2002-12-17 2008-04-30 Crucell Holland Bv A replication defective recombinant adenovirus comprising a antigenic determinant of Plasmodium falciparum wherein the antigenic determinant is SEQ ID 6
CA2903582C (en) 2013-03-14 2021-06-08 Salk Institute For Biological Studies Oncolytic adenovirus compositions
ES2837400T3 (es) 2015-10-05 2021-06-30 Salk Inst For Biological Studi Adenovirus sintético con tropismo para los tejidos dañados para su uso en la promoción de la reparación de heridas y regeneración tisular
JP7015551B2 (ja) 2016-02-23 2022-02-15 ソーク インスティテュート フォー バイオロジカル スタディーズ ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現
WO2017147265A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
CA3045892A1 (en) 2016-12-12 2018-06-21 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
WO2018125970A1 (en) * 2016-12-30 2018-07-05 Salk Institute For Biological Studies Synthetic adenoviruses targeting bone tissue and uses thereof
CN120796389A (zh) 2017-05-26 2025-10-17 埃皮森特Rx股份有限公司 携带转基因的重组腺病毒
BR112020019942A2 (pt) 2018-04-09 2021-01-26 Salk Institute For Biological Studies composições de adenovírus oncolítico com propriedades de replicação aprimoradas

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2723697B1 (fr) * 1994-08-17 1996-09-20 Rhone Poulenc Rorer Sa Methode de traitement de la restenose par la therapie genique
US5770442A (en) * 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
EP1445322B2 (en) * 1995-06-15 2012-06-06 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
IL124654A0 (en) * 1995-11-28 1998-12-06 Genvec Inc Vectors and method for gene transfer to cells
US20030017138A1 (en) * 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
EP1020529B1 (en) * 1998-11-20 2005-06-01 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
IL133032A (en) * 1998-11-20 2007-06-03 Introgene Bv Adenoviral gene delivery vectors provided with a tissue tropism for smooth muscle cells and /or endothelial cells

Similar Documents

Publication Publication Date Title
JP2002537816A5 (enExample)
McCoy et al. Pulmonary inflammation induced by incomplete or inactivated adenoviral particles
Kreppel et al. Modification of adenovirus gene transfer vectors with synthetic polymers: a scientific review and technical guide
JP4733795B2 (ja) ヒツジアデノウイルスベクターを用いた遺伝子治療
CA2074502C (en) Vaccines
ATE403006T1 (de) Verwendung eines adenovirusvektors zur transduktion von synovialen zellen
DE59913833D1 (de) Strukturprotein von aav, seine herstellung und verwendung
Xu et al. Construction of ovine adenovirus recombinants by gene insertion or deletion of related terminal region sequences
Lusky et al. Regulation of adenovirus-mediated transgene expression by the viral E4 gene products: requirement for E4 ORF3
WO2001055362A3 (en) Hybrid adeno-retroviral vector for the transfection of cells
JP2004501650A5 (enExample)
Ohga et al. Activin receptors are expressed on human lung fibroblast and activin A facilitates fibroblast-mediated collagen gel contraction
Zickler et al. Novel endogenous engineering platform for robust loading and delivery of functional mRNA by extracellular vesicles
ATE420182T1 (de) Verpackungszellinien in der verwendung zur erleichterung der entwicklung hocheffizienter adenoviraler vektoren
Flood et al. Assembly of nucleocapsids with cytosolic and membrane-derived matrix proteins of vesicular stomatitis virus
Mei et al. Two closely related adenovirus genome types with kidney or respiratory tract tropism differ in their binding to epithelial cells of various origins
Verhaagh et al. Human CD46-transgenic mice in studies involving replication-incompetent adenoviral type 35 vectors
Nilson et al. Hexon modification of human adenovirus type 5 vectors enables efficient transduction of human multipotent mesenchymal stromal cells
NO995697D0 (no) Gen-vektorer
Reddy et al. Enhanced gene transfer and oncolysis of head and neck cancer and melanoma cells by fiber chimeric oncolytic adenoviruses
Mittal et al. Pathology and immunogenicity in the cotton rat (Sigmodon hispidus) model after infection with a bovine adenovirus type 3 recombinant virus expressing the firefly luciferase gene
Fang et al. Differences in the post‐translational modifications of human papillomavirus type 6b major capsid protein expressed from a baculovirus system compared with a vaccinia virus system
AU1281902A (en) Adenoviral vectors for gene delivery in skeletal muscle cells or myoblasts
Button et al. Capsid-E2 interactions rescue core assembly in viruses that cannot form cytoplasmic nucleocapsid cores
WO2002024933A3 (en) Viral vectors having tissue tropism for t-lymphocytes, b- and mast cells